CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

modified IPAC-UHN PPEWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2794 current IPAC-UHN PPE Wiki 1.00
drug2350 Standard treatment for COVID-19 Wiki 1.00
drug1270 Ivermectin Wiki 0.24

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures

This study proposes to compare the effectiveness of two different levels of PPE in protecting front-line health care workers from self-contamination with droplets and aerosolized particles during a simulated endotracheal intubation, an aerosol-generating medical procedure.

NCT04373096 Covid19 Device: current IPAC-UHN PPE Device: modified IPAC-UHN PPE

Primary Outcomes

Description: Incidence of contamination of any part of the base clothing or exposed skin of the upper body (head or neck, forearms, arms, wrists, hands or torso)

Measure: Incidence of contamination of any part of the base clothing or exposed skin of the upper body

Time: 0-1 hour After doffing is complete

Secondary Outcomes

Description: For the purpose of this outcome, the body will be divided in the following 10 areas: a) face, b) hair or posterior aspect of the head, c) right side of the neck, d) left side of the neck, e) right arm or forearm, f) left arm or forearm, g) left wrist or hand, h) right wrist or hand, i) torso, j) right or left lower extremity.

Measure: 1) Number of body areas contaminated

Time: 0-1 hour After doffing is complete

Description: Number of discrete areas of contamination of <1 cm2 and >1 cm2

Measure: 2) Number of discrete areas of contamination of <1 cm2 and >1 cm2

Time: 0-1 hour After doffing is complete

Description: Rated by each subject on an 11-point numeric rating scale from 0 (no visibility due to fogging or physical interference of the PPE, leading to inability to perform the required procedures) to 10 (perfect visibility, no fogging or physical interference with required tasks)

Measure: 3) Visibility during the simulated procedure

Time: 0-1 hour After doffing is complete

Description: Assessed using an 11-point numeric rating scale from 0 = extremely difficult PPE made it impossible to intubate, to 10 = Absolutely no obstruction or difficulty added by the PPE

Measure: 4) Ease of intubation procedures when wearing PPE

Time: 0-1 hour After doffing is complete

Description: Assessed using an 11-point numeric rating scale from 0=felt suffocated, needed to remove the PPE before completing the task to 10 = no difficulty breathing

Measure: 5) Ease of breathing while wearing PPE

Time: 0-1 hour After doffing is complete

Description: Reported on an 11-point numeric rating scale from 0 = extremely hot, needed to remove the PPE before completing the tasks to 10= no discomfort due to temperature

Measure: 6) Thermal comfort while wearing the PPE

Time: 0-1 hour After doffing is complete

Description: Doffing violations will be documented and will be defined as performing a maneuver out of sequence, touching an item of clothing out of sequence, tearing an item of protective clothing, or touching any body part other than an item of protective clothing before performing hand hygiene.

Measure: 7) Incidence of breaching of doffing procedures

Time: 0-1 hour After doffing is complete

No related HPO nodes (Using clinical trials)